ACRS Aclaris Therapeutics, Inc.
Healthcare$4.51-0.22%ClosedMarket Cap: $543.9M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
4.05
P/S
65.15
EV/EBITDA
-7.09
DCF Value
$-0.93
FCF Yield
-9.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
76.3%
Operating Margin
-961.9%
Net Margin
-832.6%
ROE
-55.9%
ROA
-35.1%
ROIC
-46.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $2.0M | 80.2% | $-22.2M | $-19.8M | $— | — |
| Q4 null | $1.3M | 162.0% | $-22.7M | $-19.8M | $— | — |
| FY null | $7.8M | 73.3% | $-76.4M | $-64.9M | $— | — |
| Q3 null | $3.3M | 83.7% | $-17.1M | $-14.6M | $— | — |
| Q2 null | $1.8M | -4.1% | $-18.4M | $-15.4M | $— | — |
| Q1 null | $1.5M | 65.2% | $-18.1M | $-15.1M | $— | — |
| Q4 null | $9.2M | -1.0% | $-99.7M | $-96.6M | $— | — |
| FY null | $18.7M | 85.1% | $-141.9M | $-132.1M | $— | — |
| Q3 null | $4.3M | 44.6% | $-10.5M | $-7.6M | $— | — |
| Q2 null | $2.8M | 31.0% | $-12.9M | $-11.0M | $— | — |
| Q1 null | $2.4M | 23.3% | $-18.9M | $-16.9M | $— | — |
| Q4 2023 | $17.6M | 63.4% | $-4.0M | $-1.5M | $-0.02 | — |